Piperlongumine and p53-reactivator APR-246 selectively induce cell death in HNSCC by targeting GSTP1

Piperlongumine (piplartine) and analogues: Antiproliferative microtubule-destabilising agents

(2017) Mary J. Meegan et al.   EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY

Developing piperlongumine-directed glutathione S-transferase inhibitors by an electrophilicity-based strategy

(2017) Hai-Bo Wang et al.   EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY

Selective Targeting of Cancer Cells by Oxidative Vulnerabilities with Novel Curcumin Analogs

(2017) Christopher Pignanelli et al.   Scientific Reports

Using Sensors and Generators of H2O2 to Elucidate the Toxicity Mechanism of Piperlongumine and Phenethyl Isothiocyanate

(2016) Beijing K. Huang et al.   ANTIOXIDANTS & REDOX SIGNALING

Leveraging an NQO1 Bioactivatable Drug for Tumor-Selective Use of Poly(ADP-ribose) Polymerase Inhibitors

(2016) Xiumei Huang et al.   CANCER CELL

Piperlongumine as a direct TrxR1 inhibitor with suppressive activity against gastric cancer

(2016) Peng Zou et al.   CANCER LETTERS

APR-246 (PRIMA-1 MET ) strongly synergizes with AZD2281 (olaparib) induced PARP inhibition to induce apoptosis in non-small cell lung cancer cell lines

(2016) Christophe Deben et al.   CANCER LETTERS

Historical Spice as a Future Drug: Therapeutic Potential of Piperlongumine

(2016) Sahdeo Prasad et al.   CURRENT PHARMACEUTICAL DESIGN

Piperlongumine exerts cytotoxic effects against cancer cells with mutant p53 proteins at least in part by restoring the biological functions of the tumor suppressor

(2016) DEBASISH BASAK et al.   INTERNATIONAL JOURNAL OF ONCOLOGY

Structural and Biochemical Analyses Reveal the Mechanism of GlutathioneS-Transferase Pi 1 Inhibition by the Anti-cancer Compound Piperlongumine

(2016) Wayne Harshbarger et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Antileukemic effects of piperlongumine and alpha lipoic acid combination on Jurkat, MEC1 and NB4 cells in vitro

(2016) Merve Alpay et al.   Journal of Cancer Research and Therapeutics

Vitamin E, γ-tocotrienol, Protects Against Buthionine Sulfoximine-Induced Cell Death by Scavenging Free Radicals in SH-SY5Y Neuroblastoma Cells

(2016) Jen-Kit Tan et al.   NUTRITION AND CANCER-AN INTERNATIONAL JOURNAL

LKB1 inhibits HPV-associated cancer progression by targeting cellular metabolism

(2016) Q Zeng et al.   ONCOGENE

O-linked GlcNAcylation elevated by HPV E6 mediates viral oncogenesis

(2016) Qinghua Zeng et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

The role of p53 in cancer drug resistance and targeted chemotherapy

(2016) Karin Hientz et al.   Oncotarget

Targeting of Mutant p53 and the Cellular Redox Balance by APR-246 as a Strategy for Efficient Cancer Therapy

(2016) Vladimir J. N. Bykov et al.   Frontiers in Oncology

Piperlongumine Suppresses Growth and Sensitizes Pancreatic Tumors to Gemcitabine in a Xenograft Mouse Model by Modulating the NF-kappa B Pathway

(2015) Y. Wang et al.   Cancer Prevention Research

Wee-1 Kinase Inhibition Sensitizes High-Risk HPV+ HNSCC to Apoptosis Accompanied by Downregulation of MCl-1 and XIAP Antiapoptotic Proteins

(2015) N. Tanaka et al.   CLINICAL CANCER RESEARCH

Piperlongumine for Enhancing Oral Bioavailability and Cytotoxicity of Docetaxel in Triple-Negative Breast Cancer

(2015) Ketan Patel et al.   JOURNAL OF PHARMACEUTICAL SCIENCES

Reactive oxygen species and p21Waf1/Cip1 are both essential for p53-mediated senescence of head and neck cancer cells

(2015) A L Fitzgerald et al.   Cell Death & Disease

Induction of BCL2-Interacting Killer, BIK, is Mediated for Anti-Cancer Activity of Curcumin in Human Head and Neck Squamous Cell Carcinoma Cells

(2015) Yue Xi et al.   Journal of Cancer

Different Mutant/Wild-Type p53 Combinations Cause a Spectrum of Increased Invasive Potential in Nonmalignant Immortalized Human Mammary Epithelial Cells

(2015) Damian J. Junk et al.   NEOPLASIA

Targeting antioxidants for cancer therapy

(2014) Andrea Glasauer et al.   BIOCHEMICAL PHARMACOLOGY

PRIMA-1Met induces myeloma cell death independent of p53 by impairing the GSH/ROS balance

(2014) B. Tessoulin et al.   BLOOD

Mutant p53 reactivation by small molecules makes its way to the clinic

(2014) Vladimir J.N. Bykov et al.   FEBS LETTERS

Mechanism of Action of Phenethylisothiocyanate and Other Reactive Oxygen Species-Inducing Anticancer Agents

(2014) I. Jutooru et al.   MOLECULAR AND CELLULAR BIOLOGY

Gain-of-Function Mutant p53 Promotes Cell Growth and Cancer Cell Metabolism via Inhibition of AMPK Activation

(2014) Ge Zhou et al.   MOLECULAR CELL

Drug-repositioning screening identified piperlongumine as a direct STAT3 inhibitor with potent activity against breast cancer

(2014) U Bharadwaj et al.   ONCOGENE

LKB1 reduces ROS-mediated cell damage via activation of p38

(2014) H-G Xu et al.   ONCOGENE

The role of reactive oxygen species and metabolism on cancer cells and their microenvironment

(2014) Ana Costa et al.   SEMINARS IN CANCER BIOLOGY

Nrf2/ARE-mediated antioxidant actions of pro-electrophilic drugs

(2013) Takumi Satoh et al.   FREE RADICAL BIOLOGY AND MEDICINE

Impaired epithelial differentiation of induced pluripotent stem cells from ectodermal dysplasia-related patients is rescued by the small compound APR-246/PRIMA-1MET

(2013) R. Shalom-Feuerstein et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

APR-246/PRIMA-1MET inhibits thioredoxin reductase 1 and converts the enzyme to a dedicated NADPH oxidase

(2013) X Peng et al.   Cell Death & Disease

Allele-Specific p53 Mutant Reactivation

(2012) Xin Yu et al.   CANCER CELL

Overview of the therapeutic potential of piplartine (piperlongumine)

(2012) Daniel P. Bezerra et al.   EUROPEAN JOURNAL OF PHARMACEUTICAL SCIENCES

Synthesis, cellular evaluation, and mechanism of action of piperlongumine analogs

(2012) D. J. Adams et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

CDDO-Imidazolide Induces DNA Damage, G2/M Arrest and Apoptosis in BRCA1-Mutated Breast Cancer Cells

(2011) E.-H. Kim et al.   Cancer Prevention Research

Selective killing of cancer cells by a small molecule targeting the stress response to ROS

(2011) Lakshmi Raj et al.   NATURE

Exome Sequencing of Head and Neck Squamous Cell Carcinoma Reveals Inactivating Mutations in NOTCH1

(2011) N. Agrawal et al.   SCIENCE

The Mutational Landscape of Head and Neck Squamous Cell Carcinoma

(2011) N. Stransky et al.   SCIENCE

PRIMA-1 Reactivates Mutant p53 by Covalent Binding to the Core Domain

(2009) Jeremy M.R. Lambert et al.   CANCER CELL

Targeting cancer cells by ROS-mediated mechanisms: a radical therapeutic approach?

(2009) Dunyaporn Trachootham et al.   NATURE REVIEWS DRUG DISCOVERY

Mutant p53 reactivation by PRIMA-1MET induces multiple signaling pathways converging on apoptosis

(2009) J M R Lambert et al.   ONCOGENE

Association of genetic polymorphisms in glutathione S-transferases and susceptibility to head and neck cancer

(2007) Madhu Singh et al.   MUTATION RESEARCH-FUNDAMENTAL AND MOLECULAR MECHANISMS OF MUTAGENESIS